Three Or More Saccharide Radicals (e.g., Neomycin, Etc.) Patents (Class 514/39)
-
Publication number: 20030143162Abstract: A patient suffering from an endobronchial infection is treated by administering to the patient for inhalation a dose of less than about 4.0 ml of a nebulized aerosol formulation comprising from about 60 to about 200 mg/ml of an aminoglycoside antibiotic, such as tobramycin, in a physiologically acceptable carrier in a time period of less than about 10 minutes. Unit dose devices for storage and delivery of the aminoglycoside antibiotic formulations are also provided.Type: ApplicationFiled: May 17, 2002Publication date: July 31, 2003Inventors: Robert John Speirs, Barbara Ann Schaeffler, Peter Bruce Challoner
-
Publication number: 20030129261Abstract: The present invention relates to compositions for the protection, treatment and repair of connective tissues in humans and animals comprising any or all of anabolic, anti-catabolic, anti-oxidant and analgesic agents, including aminosugars, S-adenosylmethionine, arachadonic acid, GAGs, including pentosan, collagen type II, tetracyclines or tetracycline-like compounds, diacerin, super oxide dismutase, L-ergothionine, one or more avocado/soybean unsaponifiables, and an analgesic, e.g., acetaminophen, and to methods of treating humans and animals by administration of these novel compositions to humans and animals in need thereof.Type: ApplicationFiled: July 11, 2002Publication date: July 10, 2003Inventors: Todd R. Henderson, Tarek Hammad, Medhat Soliman, Barbara E. Corson, Louis Lippiello, Robert W. Henderson
-
Publication number: 20030129140Abstract: The present invention is directed to the administration of aminoglycosides. In particular, the present invention is directed to compositions and methods for the pulmonary administration of aminoglycosides. According to a preferred embodiment, compositions and methods are provided for the localized treatment of respiratory infections.Type: ApplicationFiled: December 19, 2002Publication date: July 10, 2003Inventors: Thomas E. Tarara, Jeffry G. Weers, Geraldine Venthoye
-
Publication number: 20030130211Abstract: The present invention provides compositions and methods for extending the release times and lowering the toxicity of pharmacologically active compounds. The compounds comprise a salt of the pharmacologically active compound with a lipophilic counterion and a pharmaceutically acceptable water soluble solvent combined together to form an injectable composition. The lipophilic counterion may be a saturated or unsaturated C8-C22 fatty acid, and preferably may be a saturated or unsaturated C10-C18 fatty acid. When injected into a mammal, at least a portion of the composition precipitates and releases the active compound over time. Thus, the composition forms a slowly releasing drug depot of the active compound in the mammal. Therefore, the present invention enables one to provide a controlled dose administration of the active compound for a periods of up to 15 days or even longer.Type: ApplicationFiled: October 18, 2002Publication date: July 10, 2003Inventors: Yerramilli V.S.N. Murthy, Robert H. Suva
-
Publication number: 20030118631Abstract: A soluble hemostatic gauze is made from a cotton gauze immersed in an aqueous solution of from 90% to 95% ethanol at room temperature for at least 50 minutes and then exposed to an aqueous solution of NaOH at a temperature of from 35° to 40° C. for from 90 to 150 minutes. Next the cotton gauze is kept in an aqueous solution of acetic chloride at a temperature of from 35° to 40° C. for from 90 to 150 minutes and then washed in an aqueous solution of ethanol for a sufficient time to neutralize the cotton gauze and remove residue salts from the gauze resulting in a soluble hemostatic gauze. That soluble hemostatic gauze is then dried. An antibiotic or other pharmaceutically effective agent may be linked to the gauze molecules.Type: ApplicationFiled: December 21, 2001Publication date: June 26, 2003Inventors: Gao Jing Xing, Hong Zhang Xu
-
Publication number: 20030096774Abstract: Compositions that include nucleic acid and cationic aminoglycosides and methods for their use are provided. The subject compositions are characterized by having nucleic acid complexed with a cationic aminoglycoside, where the nucleic acid is condensed. In certain embodiments, the cationic aminoglycoside is a cationic aminoglycoside antibiotic. The composition may further include one or more of: functional groups such as targeting moieties, nuclear localization or targeting peptides, endosomolytic peptides and/or one or more lipids and/or polymers, where the lipids may be provided in a manner to encapsulate the nucleic acid. The present invention also provides methods of using and preparing the nucleic acid-aminoglycoside compositions.Type: ApplicationFiled: November 21, 2001Publication date: May 22, 2003Inventors: Igor Gonda, Deepa Deshpande
-
Publication number: 20030069194Abstract: This invention relates to anti-viral agents that target RNase H substrates of reverse transcriptase and methods of using these agents to inhibit reverse transcriptase and viral replication. The invention also relates to methods for screening anti-viral agents capable of inhibiting the RNase activity of reverse transcriptase by targeting RNA-DNA hybrid substrates.Type: ApplicationFiled: August 31, 2001Publication date: April 10, 2003Inventors: Daniel S. Pilch, Tsai-Kun Li
-
Publication number: 20030022847Abstract: The present invention relates to a method for inhibiting apoptosis under ischemic condition, which comprises a step of administering antibiotics of quinolones, quinones, aminoglycosides or chloramphenicol to an individual under ischemic condition which lacks an adequate supply of oxygen and glucose. In accordance with the present invention, the antibiotics increase cell viability under hypoxic and hypoglycemic condition, assuring that they can be applied as a therapeutic agent for ischemia-associated diseases such as myocardial infarction and cerebral infarction.Type: ApplicationFiled: July 12, 2002Publication date: January 30, 2003Inventors: Jongwon Lee, Kyu-Won Kim, Jong-Kyun Lee, Sang Jong Lee
-
Publication number: 20030022366Abstract: The present invention relates to a method for increasing survival rate of cells in animal cell culture under hypoxia condition by adding antibiotics to the culture media. The method of present invention comprises a step of culturing animal cells in culture media containing antibacterial agent of quinolones, quinones, aminoglycosides or chloramphenicol at the concentration range of 0.1 to 1000 &mgr;g/ml. The invented method can be practically applied for high-density animal cell culture to produce recombinant proteins or cultured cells.Type: ApplicationFiled: July 12, 2002Publication date: January 30, 2003Inventors: Jongwon Lee, Kyu-Won Kim, Mee-Jung Han, Moo Hwan Cho, Yang-Il Kim
-
Publication number: 20030013667Abstract: The present invention relates to a therapeutic agent for ischemia which inhibits apoptosis under ischemic condition. The therapeutic agent of present invention comprises antibacterial agents of quinolones, quinones, aminoglycosides or chlorampheni-col as an active ingredient. Since the invented therapeutic agent improved the viability of cells under hypoxic and hypoglycemic condition, it can be clinically for ischemic diseases such as applied as a potentiad drug for ischemia-associated infarction and cerebral infarction.Type: ApplicationFiled: July 12, 2002Publication date: January 16, 2003Inventors: Jongwon Lee, Kyu-Won Kim, Jong-Kyun Lee, Sang Jong Lee
-
Publication number: 20020187118Abstract: Improved shaving preparations for the prevention and treatment of pseudofolliculitis barbae and ingrown hair containing glucocorticoid and an antibacterial agent. Optionally, the shaving preparation may also include a therapeutic amount of benzoyl peroxide. The present invention also provides a method for preventing and/or treating pseudofolliculitis barbae, wherein the shaving preparations of the present invention are applied to the affected area immediately before shaving, during, after or in between shaves.Type: ApplicationFiled: June 7, 2001Publication date: December 12, 2002Inventor: Virgie Bright-Ellington
-
Patent number: 6482802Abstract: The present invention is directed to using neomycin or an analogue thereof as an therapeutic agent to treat angiogenesis-related diseases, which are characterized by excessive, undesired or inappropriate angiogenesis or proliferation of endothelial cells. The present invention is also directed to pharmaceutical compositions comprising (a) neomycin or an analogue and, optionally, (b) another anti-angiogenic agent or an anti-neoplastic agent. The present invention is further directed to a method for screening neomycin analogues having anti-angiogenic activity. A preferred embodiment of the invention relates to using neomycin to treat subjects having such diseases.Type: GrantFiled: November 9, 2000Date of Patent: November 19, 2002Assignee: Endowment for Research in Human Biology, Inc.Inventors: Guo-fu Hu, Bert L. Vallee
-
Publication number: 20020168368Abstract: A composition including a purified antibody conjugated with at least one antibiotic, the antibody having an antigen-binding portion that binds at least one antigen derived from Staphylococcus or Streptococcus.Type: ApplicationFiled: June 27, 2002Publication date: November 14, 2002Inventor: Stanley A. Kim
-
Publication number: 20020169124Abstract: Compositions and methods are provided for prophylactic or therapeutic treatment of balance impairments involving neuronal damage, loss, or degeneration, preferably of vestibular ganglion neurons, in an animal by administration of an effective amount of a trkB or trkC agonist, particularly a neurotrophin, more preferably NT-4/5Type: ApplicationFiled: March 12, 2002Publication date: November 14, 2002Inventor: Wei-Qiang Gao
-
Patent number: 6475992Abstract: The invention provides a method of potentiating the activity of antibacterial agents that act on bacterial cell walls, comprising the step of administering to a subject an antibacterial agent and an aminoglycoside to attain a peak concentration of at least 4 mg/l of aminoglycoside and thereafter maintaining the aminoglycoside at a concentration of up to 4 mg/l for at least 1 hour. Compositions comprising an antibacterial agent and an aminoglycoside for efficacious treatment of bacterial infection are also provided.Type: GrantFiled: August 26, 1998Date of Patent: November 5, 2002Assignee: Pharmacy and Therapeutic Advisory Consultancy Pty LTDInventor: Allan Joseph McLean
-
Patent number: 6475993Abstract: This invention relates to a method of treating an inherited disease due to a point mutation producing a stop codon by administering an effective dose of an aminoglycoside antibiotic or a derivative thereof. Mdx mouse, which is an animal model for Duchenne muscular dystrophy, has been successfully treated with intramuscularly administered 1 and 5 mg gentamicin, which had for effect to suppress the premature stop mutation by inserting an amino acid at the stop codon. Dystrophin positive muscle fibers not different in number from those of normal mouse were detected at the dose of 5 mg gentamicin.Type: GrantFiled: December 22, 1999Date of Patent: November 5, 2002Assignee: Universite LavalInventor: Jacques P. Tremblay
-
Publication number: 20020111298Abstract: This invention relates to a moisturizing skin ointment composition consisting of polymyxin B Sulfate, bacitracin zinc, neomycin (the combination of which totals 1 ounce), hydrocortisone acetate (1 ounce) and white petrolatum (13 ounces). When combined and water evaporated, an external ointment that penetrates the skin and alleviates dry skin conditions, itching and minor scrapes and scratches is created. The properties of the antibiotic products help to promote healing of minor scrapes and scratches as well as preventing the spread of dry skin conditions. The properties of the hydrocortisone aids in the alleviation of itching associated with dry skin. Because this ointment penetrates the dermis almost immediately, the moisturizing properties of petrolatum allows the full benefit of the antibiotic products and hydrocortison to remain on/in the skin through several washings thereby alleviating the need to reapply several times a day.Type: ApplicationFiled: December 18, 2000Publication date: August 15, 2002Inventor: Joyce Ann Meeks
-
Publication number: 20020098208Abstract: The present invention relates to novel method of reducing microbial infections, especially bacterial infections, of animals, especially of aquatic animals such as fish maintained in tanks or aquaria. The present invention provides bathing and dipping methods for reducing a microbial infection of an animal with an antibiotic solution of enhanced antimicrobial activity comprising at least one chelating agent and at least one antibiotic effective against the microbial infection. The present invention also provides a method for reducing a microbial infection of an animal comprising bathing or dipping an animal having a microbial infection in an antimicrobial solution comprising the chelating agent EDTA, and at least one antibiotic, and optionally a pH buffering agent. The immersion of the aquatic animal in the antimicrobial solution containing the EDTA, antibiotic and pH buffering agent may be repeated until the microbial burden of the animal is eliminated.Type: ApplicationFiled: September 18, 2001Publication date: July 25, 2002Inventors: Richard E. Wooley, Branson W. Ritchie, Victoria V. Burnley
-
Publication number: 20020061328Abstract: The invention is directed toward a sterile bone structure for application to a bone defect site to promote new bone growth at the site comprising a partially demineralized cortical bone structure, said bone structure comprising a cross sectional surface are ranging from 85% to 95% of the original bone surface area before demineralization with the remaining partially demineralized cortical bone structure having an outer demineralized layer ranging in thickness from about 0.05 mm to about 0.14 mm and a mineralized core.Type: ApplicationFiled: December 19, 2000Publication date: May 23, 2002Inventors: Arthur A. Gertzman, Moon Hae Sunwood
-
Method for the treatment of severe chronic bronchitis (bronchietasis) with an aerosolized antibiotic
Patent number: 6387886Abstract: The present invention is directed to a method for the treatment of severe chronic bronchitis, i.e., bronchiectasis, using a concentrated aminoglycoside antibiotic formulation delivering the antibiotic to the lung endobronchial space, including alveoli, in an aerosol or dry powder having a mass medium diameter predominately between 1 to 5 microns.Type: GrantFiled: November 28, 2001Date of Patent: May 14, 2002Assignee: Chiron CorporationInventors: Alan B. Montgomery, William R. Baker -
Publication number: 20020049171Abstract: The invention provides a method of potentiating the activity of antibacterial agents that act on bacterial cell walls, comprising the step of administering to a subject an antibacterial agent and an aminoglycoside to attain a peak concentration of at least 4 mg/l of aminoglycoside and thereafter maintaining the aminoglycoside at a concentration of up to 4 mg/l for at least 1 hour. Compositions comprising an antibacterial agent and an aminoglycoside for efficacious treatement of bacterial infection are also provided.Type: ApplicationFiled: August 26, 1998Publication date: April 25, 2002Inventor: ALLAN JOSEPH MCLEAN
-
Patent number: 6284739Abstract: The instant invention provides compositions containing as active agents paromomycin in combination with gentamicin. When given in combination, the compositions appear much more effective than when given alone. Furthermore, the compositions of the invention were found to be effective against several species of Leishmania that were not effectively inhibited by the prior art compositions.Type: GrantFiled: March 3, 1994Date of Patent: September 4, 2001Inventors: Max Grogl, Lawrence Fleckenstein, Patrick McGreevy, Brian Schuster
-
Patent number: 6274555Abstract: A composition for topically treating epidermal abrasions in animals is provided consisting of bacitracin zinc utilized in a ratio of 300 milligrams, neomycin utilized in a ratio of 35 milligrams, polymycin-B sulfate in a ratio of 10,000 milligrams, and pramoxine hydrochiomide in a ration of 10 milligrams. White petroleum jelly is used as a solvent and carrier for the active ingredients. The addition of a bittering agent of bitter apple oil, or citrullus colocynthis, as a powder in a proportion of 2 to 5 grains imparts a bitter flavor to the composition such as to prevent common house pets, such as dogs or cats, from licking their wounds.Type: GrantFiled: May 15, 2000Date of Patent: August 14, 2001Inventor: Lisa A. Berdami
-
Patent number: 6248718Abstract: The invention provides a medicament for topically treating acute bacterial infections in the oral mucosa, and methods of use. The medicament comprises a dry dosage (such as a troche or powder) of one or more antibacterial agents and, preferably, one or more polyvalent metal compounds. The medicament is directly applied to the site of the infection and dissolves in saliva, within about 5 to about 15 minutes, thereby directly delivering a supratherapeutic dosage of the antibacterial agent to the infected oral tissue. Further, in a preferred embodiment the medicament directly delivers a therapeutically high concentration of a polyvalent metal compound in suspension to the infected area, thereby forming a protective barrier over the infected oral tissue.Type: GrantFiled: August 18, 1999Date of Patent: June 19, 2001Assignee: Atlantic Biomed CorporationInventor: Kee Hung Hau
-
Patent number: 6245746Abstract: Compounds are described which have efflux pump inhibitor activity. Also described are methods of using such efflux pump inhibitor compounds and pharmaceutical compositions which include such compounds.Type: GrantFiled: February 4, 1998Date of Patent: June 12, 2001Assignee: Microcide Pharmaceuticals, Inc.Inventors: Suzanne Chamberland, May Lee, Roger Leger, Ving J. Lee, Thomas Renau, Zhijia J. Zhang
-
Patent number: 6180612Abstract: Protein targets for disease intervention through inhibition of nucleic acid metabolism are disclosed. Novel polypeptides for one such target, DNA-dependent ATPase A, and novel polynucleotides encoding DNA-dependent ATPase A are disclosed. Phosphoaminoglycoside compounds which act on such protein targets to inhibit nucleic acid metabolism. In addition, screening assays for identifying compounds that inhibit nucleic acid-dependent ATPase activity, including, but not limited to, DNA-dependent ATPase A, are disclosed. Such compounds are useful in the treatment of diseases, including but not limited to cancer and infectious disease, through disruption of nucleic acid metabolism and induction of apoptosis. Moreover, methods for prevention and treatment of diseases including, but not limited to cancer and infectious disease are disclosed.Type: GrantFiled: October 27, 1998Date of Patent: January 30, 2001Assignee: The University of Virginia Patent FoundationInventors: Joel W. Hockensmith, Rohini Muthuswami
-
Patent number: 6114310Abstract: Compounds are described which have efflux pump inhibitor activity. Also described are methods of using such efflux pump inhibitor compounds and pharmaceutical compositions which include such compounds.Type: GrantFiled: January 23, 1998Date of Patent: September 5, 2000Assignee: Microcide Pharmaceuticals, Inc.Inventors: Suzanne Chamberland, May Lee, Roger Leger, Ving J. Lee, Thomas Renau, Zhijia J. Zhang
-
Patent number: 6066676Abstract: Disclosed is a method of treating problems or disorders of the human nervous system or a method of imparting an anaesthetic effect, by applying to a patient in need of such treatment a pharmaceutical composition adapted for tropical application to human skin, comprising(A) as an effective ingredient, a mixture comprising(1) an antibiotic medication;(2) an antihistamine; and(B) a physiologically acceptable carrier.Type: GrantFiled: November 3, 1999Date of Patent: May 23, 2000Inventor: James S. Bass
-
Patent number: 6037140Abstract: This invention relates to a selective medium for the culture and isolation of Gram.sup.- bacteria comprising at least one antibiotic specifically active against Gram.sup.+ bacteria and at least one bacteriocin.Type: GrantFiled: October 11, 1996Date of Patent: March 14, 2000Assignee: Pasteur Sanofi DiagnosticsInventors: Benoit Carles, Jean-Pierre Facon
-
Patent number: 5993841Abstract: Disclosed is a method of treating problems or disorders of the human nervous system or a method of imparting an anaesthetic effect, by applying to a patient in need of such treatment a pharmaceutical composition adapted for topical application to human skin, comprising(A) as an effective ingredient, a mixture comprising(1) an antibiotic medication;(2) an antihistamine; and(B) a physiologically acceptable carrier.Type: GrantFiled: May 27, 1998Date of Patent: November 30, 1999Inventor: James S. Bass
-
Patent number: 5981499Abstract: The invention provides a medicament for topically treating aphthous ulcers in the oral mucosa, and methods of use. The medicament comprises a troche or powder comprising a dry dosage of one or more antibiotics and, preferably, one or more polyvalent metal compounds. The troche or powder is directly applied to the aphthous ulcer and dissolves in saliva, within about 5 to about 15 minutes, thereby directly delivering a supratherapeutic dosage of the antibiotic to the ulcerated oral tissue. Further, in a preferred embodiment the troche/powder directly delivers a therapeutically high concentration of a polyvalent metal compound in suspension to the aphthous ulcer, thereby forming a protective barrier over the ulcerated oral tissue.Type: GrantFiled: February 20, 1998Date of Patent: November 9, 1999Assignee: Atlantic Biomed CorporationInventor: Kee Hung Hau
-
Patent number: 5929039Abstract: The present invention relates generally to a method for, and pharmaceutical compositions useful in, the prophylaxis and/or treatment of cardiac dysfunction in a mammal by the administration of an effective amount of an agent capable of blocking or inhibiting the effect or release of inositol(1,4,5)trisphosphate in cardiac tissue.Type: GrantFiled: August 5, 1996Date of Patent: July 27, 1999Assignee: Baker Medical Research InstituteInventors: Elizabeth Anne Woodcock, Karen Elizabeth Anderson, Anthony Michael Dart, Xiao-Jun Du
-
Patent number: 5900406Abstract: The invention described herein provides for methods of screening for compounds that can be used to prevent or inhibit the growth of microbial eukaryotes, particularly plant or animal pathogens. The screening methods of the invention involve the step of screening compounds for the ability to inhibit Group I intron I splicing. In addition, to directly screening for compounds that inhibit Group I intron splicing, the screening methods of the invention include screening for compounds that bind to prokaryotic 16S ribosomal RNA because of the correlation, described herein, between group I intron inhibition and binding to prokaryotic 16S ribosomal RNA. The range of possible compounds for screening by the screening methods of the invention is preferably limited to 2-deoxystreptamine derivatives.Another aspect of the invention is to provide methods of treating or preventing infections with eukaryotic microbes by administering an effective amount of a compound that inhibits group I intron splicing.Type: GrantFiled: June 8, 1994Date of Patent: May 4, 1999Assignee: NZYM, Inc.Inventors: Uwe von Ahsen, Julian E. Davies, Renee Schroeder
-
Patent number: 5883074Abstract: Methods for screening for compounds which potentiate the activity of antibacterial agents against bacteria resistant to the antibacterial agent alone, pharmaceutical compositions including such potentiators, and methods of treating bacterial infections using a combination of a potentiator and a potentiated antibacterial agent, which are useful for overcoming the resistance of a bacterial strain for an antibacterial agent.Type: GrantFiled: February 8, 1995Date of Patent: March 16, 1999Assignee: Microcide Pharmaceuticals, Inc.Inventors: Amy Boggs, Joaquim Trias, Scott Hecker
-
Patent number: 5827543Abstract: The subject invention encompasses methods for prevention and treatment of a human or lower animal subject having a urogenital disorder caused or mediated by one or more parasitic protozoa comprising administering to the subject bismuth and one or more antimicrobials. The subject invention also encompasses compositions comprising bismuth and one or more antimicrobials for the prevention and treatment of a human or lower animal subject having a urogenital disorder caused or mediated by one or more parasitic protozoa.Type: GrantFiled: December 7, 1995Date of Patent: October 27, 1998Assignee: The Procter & Gamble CompanyInventor: Jamesina Anne Fitzgerald
-
Patent number: 5801153Abstract: A method for controlling plant diseases utilizes a mixture of antibiotics and food additives or food preservatives. The mixture is sprayed on the plants twice per week for three weeks, then once every three weeks. Such a regimen has been found to cure plant diseases of bacterial, fungal and viral origin. The preferred form of the mixture has four ingredients, with the antibiotics and food additives in a ratio of from 1:1 to 1:3. The antibiotics are selected from amoxicillin trihydrate and neomycin sulfate, and the food additives are selected from sodium propionate, sorbic acid, potassium sorbate, caffeine, vanillin, ascorbic acid, L-Arginine, thymol, cupric sulfate and ammonium benzoate.Type: GrantFiled: February 20, 1996Date of Patent: September 1, 1998Inventor: Mohammed A. Badaway
-
Patent number: 5780049Abstract: The invention involves pharmaceutical compositions for topical application comprising:(a) a safe and effective amount of a pharmaceutical active; and(b) from about 0.05% to about 5% of a non-ionic polyacrylamide having a molecular wight of from about 1,000,000 to about 30,000,000.Type: GrantFiled: June 5, 1995Date of Patent: July 14, 1998Assignee: Richardson-Vicks Inc.Inventors: George Endel Deckner, Brian Scott Lombardo
-
Patent number: 5753247Abstract: Disclosed is a pharmaceutical composition intended for the topical application to human skin, comprising(A) as an effective ingredient, a mixture comprising(1) an antibiotic medication;(2) an antihistamine; and(B) a physiologically acceptable carrier.Also disclosed is a method for treatment using this composition.Type: GrantFiled: March 6, 1997Date of Patent: May 19, 1998Inventor: James S. Bass
-
Patent number: 5753713Abstract: Disclosed is a pharmaceutical composition intended for the topical application to human skin, comprising(A) as an effective ingredient, a mixture comprising(1) an antibiotic medication;(2) an antihistamine; and(B) a physiologically acceptable carrier.Also disclosed is a method for treatment using this composition.Type: GrantFiled: March 24, 1997Date of Patent: May 19, 1998Inventor: James S. Bass
-
Patent number: 5712261Abstract: A method is provided for preventing and/or treating hypertriglyceridemia, and/or atherosclerosis and/or pancreatitis resulting from hypertriglyceridemia, employing a squalene synthetase inhibitor.Type: GrantFiled: June 21, 1995Date of Patent: January 27, 1998Inventors: David R. Magnin, Scott A. Biller, John K. Dickson, Jr., R. Michael Lawrence, Richard B. Sulsky
-
Patent number: 5677288Abstract: A method is disclosed for reducing excitotoxic damage to neurons, which can occur as a result of stroke, cardiac arrest, or other events or conditions. This method involves administering an aminoglycoside that suppresses the flow of calcium ions into neurons through N-type calcium channels. To be effective for such use, an aminoglycoside must suppress N-channel activity at a potency greater than streptomycin. Aminoglycosides which meet this criterion (which includes neomycin and Gentamicin) can suppress the depolarizing activation of neurons, which in turn controls the release of glutamate, a neurotransmitter that becomes an endogenous toxin under excitotoxic conditions. Numerous aminoglycosides were tested in in vitro screening tests using brain cell membrane fragments to evaluate N-channel blocking potency.Type: GrantFiled: April 15, 1994Date of Patent: October 14, 1997Assignee: Cypros Pharmaceutical CorporationInventor: Paul J. Marangos
-
Patent number: 5662929Abstract: The invention relates to a liposomal formulation containing a therapeutic agent. The formulation of the invention when administered to animals, allows a substantial increase in antibacterial activity of the agent, through an enhanced penetration of the agent inside the bacterial cell. More specifically, the invention relates to a liposomal formulation containing at least one therapeutic agent such as an antibiotic and to a method of treatment of bacterial infections through the administration of such a formulation.Type: GrantFiled: December 23, 1994Date of Patent: September 2, 1997Assignee: Universite de MontrealInventors: Jacqueline Lagace, Christian Beaulac, Sebastien Clement-Major
-
Patent number: 5663152Abstract: The present invention provides antimicrobial compositions, especially compositions comprising an antimicrobial (microbiocidal or microbiostatic) compound and a potentiator of antimicrobial activity. Compositions of the invention combinating an antimicrobial compound and a potentiator are able to kill or inhibit the growth of microorganisms using much lower concentrations of the antimicrobial compound. The potentiator also enhances the efficacy of antimicrobial compounds against resistant strains of the microorganism.Type: GrantFiled: January 19, 1995Date of Patent: September 2, 1997Assignee: Asahi Kasei Kogyo Kabushiki KaishaInventors: Fusakazu Hayano, Isao Kubo
-
Patent number: 5648397Abstract: Disclosed is a pharmaceutical composition intended for the topical application to human skin, comprising(A) as an effective ingredient, a mixture comprising(1) an antibiotic medication;(2) an antihistamine; and(B) a physiologically acceptable carrier.Also disclosed is a method for treatment using this composition.Type: GrantFiled: March 20, 1995Date of Patent: July 15, 1997Inventor: James S. Bass
-
Patent number: 5595977Abstract: The present invention relates to novel amino glycoside salts of sucrose-octa-O-sulfonic acid of formula I:([sucrose-octa-O-sulfonic acid.sup.8- ]-[R-(NH.sub.3.sup.+).sub.x ].sub.y -M.sub.z.sup.n+) (I)(x.multidot.y)+(z.multidot.n)=8x.multidot.y.epsilon.N.vertline.[4.ltoreq.x.multidot.y.ltoreq.8], wherein N is the set of natural numbers,x.epsilon.Z.vertline.[4.ltoreq.x.ltoreq.6], wherein Z is the set of integersz.epsilon.N.vertline.[0.ltoreq.z.ltoreq.4],n.epsilon.Z.vertline.[1.ltoreq.n.ltoreq.3],wherein R is a sugar moiety of an amino glycoside and M is a metal ion or an ammonium ion, said compounds being useful for treating ulcerations of the stomach and duodenum.Type: GrantFiled: October 27, 1993Date of Patent: January 21, 1997Assignee: Dumex-Alpharma A/SInventors: Hjarne Dyrsting, Torben Koch
-
Patent number: 5593971Abstract: A method is provided for preventing or reducing the risk of hypertension in normotensive patients having insulin resistance by administering a cholesterol lowering drug, such as pravastatin, alone or in combination with an ACE inhibitor, especially one containing a mercapto moiety, such as captopril or zofenopril.Type: GrantFiled: May 22, 1995Date of Patent: January 14, 1997Assignee: E. R. Squibb & Sons, Inc.Inventors: Werner Tschollar, Cary S. Yonce, James L. Bergey, James C. Kawano
-
Patent number: 5534253Abstract: A method of improving animal health including selecting at least one L. reuteri strain, characterized by the production of .beta.-hydroxypropionaldehyde, and using the selected strain(s) along with the antibiotic, gentamycin, as an animal treatment, for example, for newly hatched poultry.Type: GrantFiled: June 7, 1995Date of Patent: July 9, 1996Assignee: Biogaia ABInventors: Ivan A. Casas, Bo Mollstam
-
Patent number: 5534408Abstract: Disclosed is a method for the inhibition of binding of a ligand to an RNA, the inhibition being mediated by a small organic molecule which binds to the RNA, thereby inhibiting ligand binding. A preferred class of small organic molecules are the 2-deoxystreptamine (2-DOS) aminoglycosides. Disclosed herein are members of the 2-DOS class that are useful for the inhibition of binding of Rev to an RNA containing an RRE. In an HIV infected cell, a consequence of the inhibition of the ability of Rev to bind to the RRE in HIV encoded transcripts is inhibition of HIV replication.Type: GrantFiled: September 24, 1993Date of Patent: July 9, 1996Assignee: University Of Massachusetts Medical CenterInventors: Michael R. Green, Maria L. Zapp, Seth Stern
-
Patent number: 5525349Abstract: Methods for preventing and treating corneal haze resulting from exposure of the eye to laser irradiation are disclosed. The methods include administration of compositions of wound healing modulators to the eye. Compositions for use in preventing and treating the corneal haze are also disclosed.Type: GrantFiled: November 1, 1994Date of Patent: June 11, 1996Assignee: Alcon Laboratories, Inc.Inventors: Stella M. Robertson, Herman M. Kunkle, Jr.
-
Patent number: 5312813Abstract: A method of killing microorganisms which form a biofilm on a tissue or implant surfaces in a patient, and which are refractory to a biocide at a dose which is effective to kill the microorganism in planktonic form. The effect of the biocide is potentiated, to an effective killing level, by applying an electric field across the surface containing the biofilm.Type: GrantFiled: July 22, 1992Date of Patent: May 17, 1994Assignee: University Technologies InternationalInventors: John W. F. Costerton, Antoine E. Khoury, Frank Johnson